David Kistenbroker

David Kistenbroker

Dechert LLP

Contact
View Bio
RSS

Latest Posts › 10b5-1 Plans

Share:

Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies

Last year marked an increase in federal securities class action filings, with plaintiffs filing 212 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019. Life sciences companies remained...more

3/28/2024  /  10b5-1 Plans , Class Action , Conflicts of Interest , Food and Drug Administration (FDA) , Fraud , Life Sciences , Misrepresentation , Securities and Exchange Commission (SEC) , Securities Violations
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide